Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation

被引:70
作者
Hasegawa, W
Pond, GR
Rifkind, JT
Messner, HA
Lau, A
Daly, AS
Kiss, TL
Kotchetkova, N
Galal, A
Lipton, JH
机构
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Allogene Bone Marrow Transplant Serv, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Biostat, Toronto, ON M5G 2M9, Canada
关键词
secondary malignancy; transplant complications;
D O I
10.1038/sj.bmt.1704706
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The purpose of this study was to evaluate the estimated incidence of secondary malignancies post-allogeneic bone marrow transplantation (BMT) in a cohort of adult patients previously reported now with an additional 8.5 years of follow-up. A cohort of 557 patients older than age 16 years underwent allogeneic BMT between June 1970 and November 1993. Histologic reports confirmed the diagnosis of a secondary malignancy. Multivariate Cox proportional hazards method was utilized to investigate predictors for the development of secondary malignancies. In all, 31 patients in this cohort developed a secondary malignancy a median of 6.79 years after their transplant. The estimated cumulative incidence rate of secondary malignancy was 4.2% at 10 years post transplant. When compared to the general population, the estimated observed/expected ratio of new cancer diagnoses was 5.13. On multivariate analysis, older age at the time of transplant was the only significant predictor for development of secondary cancer (P=0.01). The most common malignancies observed were nonmelanomatous skin cancers and squamous cell cancers of the buccal cavity. The risk of developing a secondary malignancy after allogeneic BMT is significant, particularly in older patients. Long-term survivors of transplant require regular monitoring for early signs of cancer, particularly of the skin and oral cavity.
引用
收藏
页码:51 / 55
页数:5
相关论文
共 16 条
[1]   Malignant neoplasms following bone marrow transplantation [J].
Bhatia, S ;
Ramsay, NKC ;
Steinbuch, M ;
Dusenbery, KE ;
Shapiro, RS ;
Weisdorf, DJ ;
Robison, LL ;
Miller, JS ;
Neglia, JP .
BLOOD, 1996, 87 (09) :3633-3639
[2]  
*CANC CAR ONT, 2002, ONT CANC REG
[3]   Solid cancers after bone marrow transplantation [J].
Curtis, RE ;
Rowlings, PA ;
Deeg, HJ ;
Shriner, DA ;
Socie, G ;
Travis, LB ;
Horowitz, MM ;
Witherspoon, RP ;
Hoover, RN ;
Sobocinski, KA ;
Fraumeni, JF ;
Boice, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :897-904
[4]   RISK-FACTORS FOR THE DEVELOPMENT OF SECONDARY MALIGNANCIES AFTER MARROW TRANSPLANTATION [J].
DEEG, HJ ;
WITHERSPOON, RP .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (02) :417-429
[5]   Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients [J].
Deeg, HJ ;
Socie, G ;
Schoch, G ;
HenryAmar, M ;
Witherspoon, RP ;
Devergie, A ;
Sullivan, KM ;
Gluckman, E ;
Storb, R .
BLOOD, 1996, 87 (01) :386-392
[6]   Malignancies after hematopoietic stem cell transplantation:: Many questions, some answers [J].
Deeg, HJ ;
Socié, G .
BLOOD, 1998, 91 (06) :1833-1844
[7]   Treatment of solid tumors following allogeneic bone marrow transplantation [J].
Favre-Schmuziger, G ;
Hofer, S ;
Passweg, J ;
Tichelli, A ;
Hoffmann, T ;
Speck, B ;
Herrmann, R ;
Gratwohl, A .
BONE MARROW TRANSPLANTATION, 2000, 25 (08) :895-898
[8]  
Kolb H J, 1997, Curr Opin Hematol, V4, P401
[9]  
KOLB HJ, 1990, BONE MARROW TRANSPL, V6, P61
[10]   Malignant neoplasms in long-term survivors of bone marrow transplantation [J].
Kolb, HJ ;
Socié, G ;
Duell, T ;
Van Lint, MT ;
Tichelli, A ;
Apperley, JF ;
Nekolla, E ;
Ljungman, P ;
Jacobsen, N ;
van Weel, M ;
Wick, R ;
Weiss, M ;
Prentice, HG .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (10) :738-+